Elizabeth Leick


Expert Discusses Value of Venetoclax After BCR Inhibition in CLL

February 3rd 2017

Jeffrey Jones, MD, discusses promising early data for venetoclax in chronic lymphocytic leukemia after progression on BCR-pathway inhibitors, as well as the next steps with the research.

Expert Touts Value of Lenalidomide Maintenance in Myeloma

January 19th 2017

Lenalidomide as a maintenance treatment for patients with newly diagnosed symptomatic multiple myeloma demonstrated encouraging phase III findings in the Myeloma X1 trial, which were presented at the 2016 ASH Annual Meeting.

Hodgkin Lymphoma Field Evolving With Immunotherapy, Adjustments to Standard Approaches

January 18th 2017

Since the FDA approval of nivolumab in May 2016, researchers continue to explore agent as well as its fellow PD-1 inhibitor, pembrolizumab, in various treatment settings for patients with Hodgkin lymphoma.

Landscape for Myeloproliferative Disorders Becoming More Defined With Improved Treatments, Biomarkers

January 11th 2017

Emerging therapies in myeloproliferative disorders such as chronic myeloid leukemia, polycythemia vera, and myelofibrosis could have the potential to shake up the landscape.

T-Cell Lymphoma Options Burgeoning With Ongoing Clinical Trials

January 7th 2017

Though T-cell lymphoma is a more rare hematologic malignancy, researchers are exploring therapies such as brentuximab vedotin to improve outcomes for these patients.

Novel Therapies Likely to Transform AML Landscape

January 4th 2017

A combination regimen of the BCL-2 inhibitor venetoclax plus low-dose cytarabine demonstrated an acceptable safety and pharmacokinetic profile in elderly patients with treatment-naïve acute myeloid leukemia.

Evolution Anticipated in First-Line Treatment for CLL, Indolent Lymphomas

January 3rd 2017

Novel therapies are being investigated in 2 areas of hematologic malignancies, but the first-line setting is where the brunt of research needs to be conducted.